13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q3 2019. See the latest, Q3 2026 →

Reported value

$8.83B

−20% on the quarter before

Positions

32

3 new, 3 sold out

Top 10

70.7%

of the value

Est. gain

−$856.5M

on stocks held all quarter

Est. return

−9.7%

on those stocks since Q2 2019

Filed

Nov 13, 2019

On SEC EDGAR ↗

Positions as of Sep 30, 2019, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2019. Striped tiles are options.

Liberty Global Plc12%
Viasat Inc12%
Fox Corp9.8%
Ebay Inc7.3%
Cheniere Energy Inc7.2%
Bristol Myers Squibb Co5.7%
Cbs Corp New5.5%
Qorvo4.8%Tesla3.4%
Colony Cap Inc New3.4%
8 others3.0%
Pg&E Corp2.8%
Nexstar Media Group Inc2.3%
Univar Solutions Inc2.2%
Liberty Global Plc2.1%
Theravance Biopharma Inc2.1%
Fox Corp2.0%
Mckesson Corp2.0%
Translate Bio Inc2.0%
Synchrony Finl1.9%
Takeda Pharmaceutical Co Ltd1.8%
Nuance Communications Inc1.5%
Atara Biotherapeutics Inc1.3%
Amerisourcebergen Corp1.1%
Akebia Therapeutics Inc1.1%

Largest buys

Since Q2 2019, sized at quarter-end prices.

  1. Nuance Communications Inc~$134.5MNew, 0.0% → 1.5% of the portfolio+8,245,456 shares
  2. Translate Bio Inc~$85.4MAdded, 1.0% → 2.0% of the portfolio+8,700,000 shares
  3. Cbs Corp New~$80.7MAdded, 4.5% → 5.5% of the portfolio+2,000,000 shares
  4. Nexstar Media Group Inc~$61.6MAdded, 1.3% → 2.3% of the portfolio+602,245 shares
  5. Liberty Global Plc~$48.1MAdded, 10.1% → 11.8% of the portfolio+2,020,621 shares
  6. Vista Oil & Gas S A B De C V~$31.9MNew, 0.0% → 0.4% of the portfolio+6,175,000 shares
  7. Cars Com Inc~$26.9MNew, 0.0% → 0.3% of the portfolio+3,000,000 shares
  8. Atara Biotherapeutics Inc~$18.5MAdded, 1.3% → 1.3% of the portfolio+1,308,900 shares
  9. Liberty Global Plc~$5.4MAdded, 1.8% → 2.1% of the portfolio+216,500 shares

Largest sells

Since Q2 2019, sized at quarter-end prices.

  1. Allergan Plc~$616.1MSold out, 5.6% → 0.0% of the portfolio−3,679,549 shares
  2. Ebay Inc~$292.3MCut, 8.6% → 7.3% of the portfolio−7,500,000 shares
  3. Qorvo~$222.4MCut, 5.2% → 4.8% of the portfolio−3,000,000 shares
  4. Mckesson Corp~$176.2MCut, 3.2% → 2.0% of the portfolio−1,289,000 shares
  5. Bristol Myers Squibb Co~$152.1MCut, 5.3% → 5.7% of the portfolio−3,000,000 shares
  6. Synchrony Finl~$145.1MCut, 2.9% → 1.9% of the portfolio−4,256,576 shares
  7. Xpo Logistics Inc~$86.7MSold out, 0.8% → 0.0% of the portfolio−1,500,000 shares
  8. Amerisourcebergen Corp~$86.3MCut, 1.7% → 1.1% of the portfolio−1,047,893 shares
  9. Cheniere Energy Inc~$33.7MCut, 6.6% → 7.2% of the portfolio−535,002 shares
  10. Sinclair Broadcast Group Inc~$29.5MSold out, 0.3% → 0.0% of the portfolio−549,423 shares

Holdings

As of Sep 30, 2019; changes in shares since Jun 30, 2019.

Positions, sorted by share of the portfolio
HoldingValue
Liberty Global PlcSHS CL C · shares +4.8% · price −10.3%11.8%$1.05B−$114.9M
Viasat IncCOM · shares 0% · price −6.8%11.7%$1.03B−$75.5M
Fox CorpCL A COM · shares 0% · price −13.9%9.8%$861.6M−$139.5M
Ebay IncCOM · shares −31% · price −1.3%7.3%$648.9M−$8.7M
Cheniere Energy IncCOM NEW · shares −5.0% · price −7.9%7.2%$639.4M−$54.7M
Bristol Myers Squibb CoCOM · shares −23% · price +11.8%5.7%$507.1M+$53.6M
Cbs Corp NewCL B · shares +20% · price −19.1%5.5%$484.4M−$95.3M
QorvoCOM · shares −35% · price +11.3%4.8%$421.2M+$42.8M
TeslaNOTE 2.375% 3/1 · shares 0% · price +2.7%3.4%$303.5M—
Colony Cap Inc NewCL A COM · shares 0% · price +20.4%3.4%$299.1M+$50.7M
Pg&E CorpCOM · shares 0% · price −56.4%2.8%$245.0M−$316.5M
Nexstar Media Group IncCL A · shares +43% · price +1.3%2.3%$204.6M+$1.8M
Univar Solutions IncCOM · shares 0% · price −5.8%2.2%$197.2M−$12.2M
Liberty Global PlcSHS CL A · shares +2.9% · price −8.3%2.1%$189.5M−$16.7M
Theravance Biopharma IncCOM · shares 0% · price +19.3%2.1%$181.3M+$29.3M
Fox CorpCL B COM · shares 0% · price −13.7%2.0%$179.2M−$28.3M
Mckesson CorpCOM · shares −50% · price +1.7%2.0%$178.5M+$3.0M
Translate Bio IncCOM · shares +98% · price −20.6%2.0%$172.2M−$22.5M
Synchrony FinlCOM · shares −46% · price −1.7%1.9%$170.6M−$2.9M
Takeda Pharmaceutical Co LtdSPONSORED ADS · shares −0.03% · price −2.8%1.8%$162.3M−$4.7M
Nuance Communications IncCOM · shares New1.5%$134.5M—
Atara Biotherapeutics IncCOM · shares +19% · price −29.8%1.3%$117.3M−$41.9M
Amerisourcebergen CorpCOM · shares −47% · price −3.4%1.1%$96.0M−$3.4M
Akebia Therapeutics IncCOM · shares 0% · price −19.0%1.1%$95.9M−$22.5M
Veritiv CorpCOM · shares 0% · price −6.9%0.73%$64.4M−$4.8M
Total 32 positions100%$8.83B−$856.5M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2019 to Q3 2019: 27 stocks held throughout, down $856.5M (−9.7%).

  1. Bristol Myers Squibb Co+$53.6M+12%
  2. Colony Cap Inc New+$50.7M+20%
  3. Qorvo+$42.8M+11%
  4. Theravance Biopharma Inc+$29.3M+19%
  5. Mckesson Corp+$3.0M+2%
  6. Viasat Inc−$75.5M−7%
  7. Cbs Corp New−$95.3M−19%
  8. Liberty Global Plc−$114.9M−10%
  9. Fox Corp−$139.5M−14%
  10. Pg&E Corp−$316.5M−56%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free